Navigation Links
STAAR Surgical Builds Leadership Team to Drive Growth Opportunities
Date:9/4/2012

MONROVIA, Calif., Sept. 4, 2012 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced key additions to its senior management team as it builds a stronger foundation to drive growth opportunities.  James Francese (48) has joined STAAR Surgical as V.P. of Global Marketing; Robin Hughes (48) has been named V.P. of Research and Development, Regulatory and Quality; and Craig Felberg (61) has been named V.P. of Business Development.

"These leadership transitions are designed to help fuel our revenue growth in three ways: more effectively and aggressively market STAAR products globally, bring new products to market more quickly and evaluate additional new technologies and business opportunities which will allow us to grow within our area of strategic focus," said CEO Barry Caldwell.

Mr. Francese has 22 years of experience in ophthalmology, including 14 years marketing surgical products with Abbott Medical Optics, formerly Advanced Medical Optics (AMO) and Allergan.  During his time at AMO, Mr. Francese held several positions of executive level responsibilities, including Head of Marketing, Americas for all surgical, refractive and corneal products, Head of Global Corneal Marketing responsible for all consumer products, and V.P. of Asia Pacific Region where he had full P&L responsibility for cataract and refractive during his tenure. He received his Bachelor of Science degree from Cornell University, Master of Science degree from the University of Washington and Master of Business Administration degree from the University of Southern California. Mr. Caldwell stated, "Jim is an excellent addition to the STAAR team and his experience in refractive, cataract and consumer products will be very valuable for our strategic product growth plans.  His experience in consumer products will add to our ability to drive Visian ICL sales through consumer awareness campaigns and his background in technology will also assist in marketing efforts to more aggressively develop new key messaging on our Collamer based technologies.  Jim is very well respected in the industry by both surgeons and his colleagues."

Mr. Hughes has over 20 years of experience in the ophthalmic industry including the past five as V.P. of Global Marketing at STAAR.  His scientific background includes qualifications in medical microbiology from The Royal London Hospital, and in human physiology and cell biology from the University of Westminster. He also earned a Master of Business Administration from Henley Management College. "Robin has demonstrated a keen sense for ophthalmic technologies and will manage the new product organic growth plans very effectively.  These plans include the Visian ICL enhancements in V5 and V6 and enhanced nanoFLEX designs for the short term.  He will also bring an enhanced skill set to focus and manage the complex global regulatory requirements for commercialization of our new products," continued Mr. Caldwell.

Mr. Felberg will lead a Business Development team consisting of STAAR's General Counsel Sam Gesten, Robin Hughes and CEO Barry Caldwell.  He has 30 years of experience in the ophthalmic surgical business including the past five years as V.P. of Research and Development at STAAR. He received his Bachelor of Arts in Management from the University of Redlands and Master of Business Administration from Pepperdine University. Mr. Caldwell added, "Craig's experience in ophthalmic surgical technologies will be a significant asset as he leads the effort to identify and evaluate outside technology opportunities within our strategic focus of lenses that go into the eye and related delivery systems.  This is a new position which is key in our plans to obtain the rights to innovative technologies which can add to our growth strategies.  There are some very innovative technologies evolving around the world and Craig's leadership will allow us to properly evaluate these opportunities." 

About STAAR SurgicalSTAAR, which has been dedicated solely to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye.  All of these lenses are foldable, which permits the surgeon to insert them through a small incision.  STAAR's lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer® Lens or "ICL."  A lens used to replace the natural lens after cataract surgery is called an intraocular lens or "IOL."  Over 300,000 Visian ICLs have been implanted to date; to learn more about the ICL go to: www.visianinfo.com.  STAAR has approximately 300 full time employees and markets lenses in approximately 60 countries.  Headquartered in Monrovia, CA, it manufactures in the following locations: Nidau, Switzerland; Ichikawa City, Japan; Aliso Viejo, CA; and Monrovia, CA.  For more information, please visit the Company's website at www.staar.com or call 626-303-7902. 

Collamer® is the registered trademark for STAAR's proprietary biocompatible collagen copolymer lens material.  CONTACT:

InvestorsMediaEVC GroupEVC GroupDouglas Sherk, 415-652-9100

Chris GaleJenifer Kirtland, 415-568-9349 

646-201-5431


'/>"/>
SOURCE STAAR Surgical Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. STAAR Surgical Expands Footprint for Growth with Lease on Adjacent Building in Monrovia, California
2. STAAR Surgical To Present At The 32nd Annual Canaccord Growth Conference
3. STAAR Surgical Reports Second Quarter 2012 Financial Results
4. STAAR Surgical Provides Outlook On Second Quarter 2012 Financial Results
5. STAAR Surgical To Present At The Benchmark And Jefferies Investor Conferences
6. B. Riley Revises Timing of STAAR Surgical Presentation at Investor Conference
7. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
8. STAAR Surgical Celebrates Over 300,000 Successful Visian® ICL Implants at ASCRS Congress
9. Millennium Surgical Corp. Named to Inc. 5000 List of Fastest Growing Private Companies for The Second Year
10. Surgical Equipment Market (Surgical Sutures, Surgical Hand Instruments and Electrosurgical Devices) - Global forecast, Market Share, size, growth and industry analysis (2010-2017)
11. Regional Medical Center at Memphis Completes Rapid Six-Month Implementation of Comprehensive Perioperative and Anesthesia Solution from Surgical Information Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017 Summary ... understand Bayer and its partnering interests and activities since 2010. ... provides an in-depth insight into the partnering activity of one ... demand company reports are prepared upon purchase to ensure inclusion ... The report will be delivered in PDF format ...
(Date:3/27/2017)... , March 27, 2017  Cryoport, Inc. (NASDAQ: ... it intends to offer shares of common stock in ... statement on file with the Securities and Exchange Commission ... other conditions, and there can be no assurance as ... or as to the actual size or terms of ...
(Date:3/27/2017)... new survey from the American Association of ... (CBP) significantly reduced beneficiary choice and access to commonly ... beneficiaries to switch to unfamiliar or unsuitable testing systems, ... AADE,s survey is the latest in a continuous round ... inherent problems with the CBP. Last year, a National ...
Breaking Medicine Technology:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... today announced it will co-exhibit with technology partners LG Business Solutions at ... Marriott Metro Center in Washington D.C., will provide education and examination into the ...
(Date:3/27/2017)... ... 2017 , ... M&S Technologies, the first name in computerized ... System® 20/20. CE Certification builds upon M&S's long-standing commitment to products and software ... ISO and proven test methods used in the field of Vision Care. Smart ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may be ... groin injury, it occurs when the muscles around the pelvis become inflamed. Over ... the lower torso, as well as accompanying tenderness and weakness. Without proper intervention, ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... epigenetic research products enables researchers to pursue the recent RNA methylation “gold rush” ... . In light of the newfound characteristics of N6-methyladenosine, or m6A , ...
(Date:3/27/2017)... ... ... Schloz is still in shock after receiving a $2,500 Academic Award from California Casualty ... said. , She thinks the coming week is going to be a very joyful for ... help my students.” , The award will allow the 4th grade teacher at Tumwater Hill ...
Breaking Medicine News(10 mins):